152 361

Cited 0 times in

S-1 Monotherapy as a Neoadjuvant Treatment for Locally Advanced Gastric Cancer

Authors
 Jong Yul Jung  ;  Sun Young Rha  ;  Joong Bae Ahn  ;  Woo Ick Yang  ;  Sung Hoon Noh  ;  Hyun Cheol Chung  ;  Hei-Cheul Jeung 
Citation
 KOREAN JOURNAL OF INTERNAL MEDICINE, Vol.23(1) : 37-41, 2008 
Journal Title
 KOREAN JOURNAL OF INTERNAL MEDICINE 
ISSN
 1226-3303 
Issue Date
2008
MeSH
• Adenocarcinoma/drug therapy* ; Adenocarcinoma/pathology ; Adenocarcinoma/surgery ; Aged ; Antimetabolites, Antineoplastic/administration & dosage ; Antimetabolites, Antineoplastic/therapeutic use* ; Drug Combinations ; Gastrectomy ; Humans ; Male ; Neoadjuvant Therapy* ; Neoplasm Staging ; Oxonic Acid/administration & dosage ; Oxonic Acid/therapeutic use* ; Stomach Neoplasms/drug therapy* ; Stomach Neoplasms/pathology ; Stomach Neoplasms/surgery ; Tegafur/administration & dosage ; Tegafur/therapeutic use*
Keywords
Gastric cancer ; S-1 ; Neoadjuvant therapy
Abstract
S-1, a novel oral fluoropyrimidine, is an effective therapeutic agent for gastric cancer. Herein, we report a case with locally advanced gastric cancer that achieved a curative resection after S-1 monotherapy as neoadjuvant treatment. A 68-year-old man was diagnosed with gastric cancer and massive lymphadenopathy involving the perigastric, celiac axis and splenic hilum. His clinical stage was cT3N2H0P0M0. Considering his relatively poor performance (ECOG 2, severe weight loss) and advanced age, we started the patient on S-1 monotherapy at a dose of 35 mg/m2 bid for 4 consecutive weeks followed by a 2-week rest. Follow-up study after 4 treatment cycles revealed disappearance of the lymphadenopathy of the perigastric and celiac axis with diminished extension of the stomach mass. The patient had a partial response (PR) with a 72% tumor reduction, according to the Response Evaluation Criteria in Solid Tumors (RECIST). His performance status was improved to an ECOG 1 and he gained 7 kg. A curative (R0) resection was achieved with a radical total gastrectomy and D2 dissection. The pathological stage was pT3N2M0, stage IIIB. In conclusion, S-1 neoadjuvant chemotherapy aided in the treatment of gastric cancer in this patient.
Files in This Item:
T200800586.pdf Download
DOI
10.3904/kjim.2008.23.1.37
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Pathology (병리학교실) > 1. Journal Papers
Yonsei Authors
Noh, Sung Hoon(노성훈) ORCID logo https://orcid.org/0000-0003-4386-6886
Rha, Sun Young(라선영) ORCID logo https://orcid.org/0000-0002-2512-4531
Ahn, Joong Bae(안중배) ORCID logo https://orcid.org/0000-0001-6787-1503
Yang, Woo Ick(양우익) ORCID logo https://orcid.org/0000-0002-6084-5019
Jung, Jong Yul(정종열)
Chung, Hyun Cheol(정현철) ORCID logo https://orcid.org/0000-0002-0920-9471
Jeung, Hei Cheul(정희철) ORCID logo https://orcid.org/0000-0003-0952-3679
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/106812
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse